Health and Family Planning Commission of Guangdong Report issue

Government Phase 4

Organization Overview

First Clinical Trial
2016
NCT02638896
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (3)

celecoxib (celebrex) (1 trial)

etanercept (enbrel) (1 trial)

sulfasalazine (azulfidine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Spondylitis (Phase 4)

Spondylitis, Ankylosing (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 3